Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone

OBJECTIVE: To evaluate the achievement of comprehensive disease control (CDC) following 1 year of treatment with adalimumab+methotrexate versus methotrexate alone and whether early achievement of remission (at week 24 or 26) is associated with CDC at week 52 in patients with either early or establis...

Descripción completa

Detalles Bibliográficos
Autores principales: Keystone, Edward C, Breedveld, Ferdinand C, van der Heijde, Désirée, van Vollenhoven, Ronald F, Emery, Paul, Smolen, Josef S, Sainsbury, Iain, Florentinus, Stefan, Kupper, Hartmut, Chen, Kun, Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623327/
https://www.ncbi.nlm.nih.gov/pubmed/29018564
http://dx.doi.org/10.1136/rmdopen-2017-000445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623327/
https://www.ncbi.nlm.nih.gov/pubmed/29018564
http://dx.doi.org/10.1136/rmdopen-2017-000445

Ejemplares similares